JNJ: Johnson & Johnson

JNJ News

• 23:00 Johnson & Johnson: A 6.9 Rating and What It Means for Investors
• 06:07 September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog
• 23:05 Jennifer Taubert, evp of Johnson & Johnson, sells $10m in stock
• 23:03 Dividend Champion, Contender, And Challenger Highlights: Week Of September 7
• 21:37 Kenvue fights back against RFK Jr.’s Tylenol safety concerns as its stock tumbles
• 14:53 BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
• 13:07 Pfizer: Still A Bargain Despite Kennedy's Anti-Vaccine Attacks (NYSE:PFE)
• 12:15 Campbell’s appoints Kelly Palumbo as chief accounting officer, details compensation
• 14:46 Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?
• 13:17 Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
• 08:39 Guggenheim initiates ORIC Pharmaceuticals stock with Buy rating on cancer drug potential
• 08:09 Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
• 18:27 Johnson & Johnson stock price target raised to $195 from $175 at Wolfe Research
• 18:09 Factbox-Global drugmakers rush to boost US presence as tariff threat looms
• 16:15 Gilead starts building manufacturing hub under $32 billion planned US investments
• 14:04 J&J Gears Up for Some Key New Drug Approvals and Launches
• 19:00 Johnson & Johnson Scores With Heart Pump Breakthrough
• 14:42 Johnson & Johnson Showcases Positive AFib Data, Treatment Results - Johnson & Johnson (NYSE:JNJ)
• 14:10 Glaukos Builds Dual Growth Engines Amid Market Headwinds
• 14:01 Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
• 09:16 Johnson & Johnson (JNJ) Says Trial Shows Its Heart Pump Could Keep Patients Alive Longer - TipRanks.com
• 10:11 Vimian Group AB shares rise after winning $40 million court decision
• 18:10 These 4 Dividend Stocks Are Money-Printing Machines
• 18:00 Johnson & Johnson Ends RA Combo After Mid-Stage Miss